Challenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-limited Settings: Conclusions From the Council for International Organizations of Medical Sciences–Ibero-American Network of Pharmacogenetics and Pharmacogenomics Meeting

Peñas-Lledó, Eva; Terán, Enrique; Sosa-Macías, Marta; Galavíz-Hernández, Carlos; Gil, José Pedro; Nair, Sreejayan; Diwakar, Shyam; Hernández, Isabel; Lara-Riegos, Julio; Ramírez-Roa, Ronald; Verde, Ignácio; Tarazona‐Santos, Eduardo; Molina-Güarneros, Juan; Moya, Graciela; Rägo, Lembit; LLerena, Adrián

doi:10.1016/j.clinthera.2020.06.008

Cited by 13 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The future of precision medicine initiatives in Africa is dependent on a better understanding of native pharmacogenetic specificities. 22 Studies like the present one showcases the pharmacogenetic diversity of the continent and the need of its better characterization.…”

Section: Dovepressmentioning

confidence: 70%

Prevalence of CYP2C82 and 3 among Eritreans and its Potential Impact on Artesunate/Amodiaquine Treatment

Habtemikael

Russom

Bahta

et al. 2020

PGPM

View full text Add to dashboard Cite

Background In Eritrea, artesunate–amodiaquine is the first-line treatment against uncomplicated malaria. Amodiaquine, which is mainly bio-transformed by CYP2C8, is known to be associated with adverse events of different severity. Extrapyramidal events are among the less common but have been reported with non-negligible frequency in Eritrea. This study was conducted to investigate the allele frequencies of CYP2C8*2 and *3 , both associated with decreased amodiaquine metabolism, among the Eritrean population. Methods During September–November 2018, dried blood samples from 380 participants and 17 patients who previously had experienced extrapyramidal symptoms following treatment of artesunate–amodiaquine were collected and PCR-RFLP genotyped for CYP2C8*2 and *3 . Results The allele frequencies of CYP2C8*2 and *3 were determined as 5.9% (95% CI: 4.4–7.8) and 4.6% (95% CI: 3.2–6.3), respectively. Four out of the 17 patients with extrapyramidal reactions showed to be carriers of the alleles. Conclusion CYP2C8*2 and *3 frequencies among Eritreans were found to be intermediate between the documented for Caucasian and African populations. These findings, along with the alleles not being decisive for the occurrence of extrapyramidal events, might be of importance regarding the amodiaquine-containing malaria treatment in Eritrea. Furthermore, it suggests a significant proportion of slow amodiaquine metabolizers in the Sahel region, information of potential interest in the context of amodiaquine-involving seasonal malaria chemoprevention.

show abstract

Section: Dovepressmentioning

confidence: 70%

Prevalence of CYP2C82 and 3 among Eritreans and its Potential Impact on Artesunate/Amodiaquine Treatment

Habtemikael

Russom

Bahta

et al. 2020

PGPM

View full text Add to dashboard Cite

show abstract

“…There are various global clinical trials carried out on Withania somnifera, including aging and safety studies. The opportunities and challenges in resource-limited clinical trials have been discussed elsewhere [164]. Herein, in Table 2, we have summarized the various clinical trials adapted from www.clinicaltrials.gov (accessed on 26 December 2023) [165], Australia New Zealand Clinical Trial Registry www.anzctr.org.au/ (accessed on 26 December 2023) [166], and International Clinical Trial Registry Platform www.who.int/clinical-trialsregistry-platform (accessed on 26 December 2023) [167] for the benefit of the reader.…”

Section: Clinical Studies On Withania Somniferamentioning

confidence: 99%

Emerging Vistas for the Nutraceutical Withania somnifera in Inflammaging

Basudkar,

Gujrati,

Ajgaonkar

et al. 2024

Pharmaceuticals

Self Cite

View full text Add to dashboard Cite

Inflammaging, a coexistence of inflammation and aging, is a persistent, systemic, low-grade inflammation seen in the geriatric population. Various natural compounds have been greatly explored for their potential role in preventing and treating inflammaging. Withania somnifera has been used for thousands of years in traditional medicine as a nutraceutical for its numerous health benefits including regenerative and adaptogenic effects. Recent preclinical and clinical studies on the role of Withania somnifera and its active compounds in treating aging, inflammation, and oxidative stress have shown promise for its use in healthy aging. We discuss the chemistry of Withania somnifera, the etiology of inflammaging and the protective role(s) of Withania somnifera in inflammaging in key organ systems including brain, lung, kidney, and liver as well as the mechanistic underpinning of these effects. Furthermore, we elucidate the beneficial effects of Withania somnifera in oxidative stress/DNA damage, immunomodulation, COVID-19, and the microbiome. We also delineate a putative protein–protein interaction network of key biomarkers modulated by Withania somnifera in inflammaging. In addition, we review the safety/potential toxicity of Withania somnifera as well as global clinical trials on Withania somnifera. Taken together, this is a synthetic review on the beneficial effects of Withania somnifera in inflammaging and highlights the potential of Withania somnifera in improving the health-related quality of life (HRQoL) in the aging population worldwide.

show abstract

“…However, clinical trials involving diabetes-associated noncoding RNAs are relatively fewer in number (57 as of May 2022). We have previously discussed the challenges and opportunities in clinical trials in resource-limited settings, which help to understand the relevance of various factors that play crucial roles in ensuring good clinical practice [ 143 ]. Noncoding RNAs, including microRNAs and lncRNAs, were evaluated from different biological matrices such as plasma, serum, tissues, cord blood, etc.…”

Section: Clinical Trials On Diabetes-associated Noncoding Rnasmentioning

confidence: 99%

Current Insights into miRNA and lncRNA Dysregulation in Diabetes: Signal Transduction, Clinical Trials and Biomarker Discovery

Pandey¹,

Ajgaonkar²,

Jadhav³

et al. 2022

Pharmaceuticals

View full text Add to dashboard Cite

Diabetes is one of the most frequently occurring metabolic disorders, affecting almost one tenth of the global population. Despite advances in antihyperglycemic therapeutics, the management of diabetes is limited due to its complexity and associated comorbidities, including diabetic neuropathy, diabetic nephropathy and diabetic retinopathy. Noncoding RNAs (ncRNAs), including microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), are involved in the regulation of gene expression as well as various disease pathways in humans. Several ncRNAs are dysregulated in diabetes and are responsible for modulating the expression of various genes that contribute to the ‘symptom complex’ in diabetes. We review various miRNAs and lncRNAs implicated in diabetes and delineate ncRNA biological networks as well as key ncRNA targets in diabetes. Further, we discuss the spatial regulation of ncRNAs and their role(s) as prognostic markers in diabetes. We also shed light on the molecular mechanisms of signal transduction with diabetes-associated ncRNAs and ncRNA-mediated epigenetic events. Lastly, we summarize clinical trials on diabetes-associated ncRNAs and discuss the functional relevance of the dysregulated ncRNA interactome in diabetes. This knowledge will facilitate the identification of putative biomarkers for the therapeutic management of diabetes and its comorbidities. Taken together, the elucidation of the architecture of signature ncRNA regulatory networks in diabetes may enable the identification of novel biomarkers in the discovery pipeline for diabetes, which may lead to better management of this metabolic disorder.

show abstract

Challenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-limited Settings: Conclusions From the Council for International Organizations of Medical Sciences–Ibero-American Network of Pharmacogenetics and Pharmacogenomics Meeting

Cited by 13 publications

References 29 publications

<p>Prevalence of <em>CYP2C82</em> and <em>3</em> among Eritreans and its Potential Impact on Artesunate/Amodiaquine Treatment</p>

<p>Prevalence of <em>CYP2C82</em> and <em>3</em> among Eritreans and its Potential Impact on Artesunate/Amodiaquine Treatment</p>

Emerging Vistas for the Nutraceutical Withania somnifera in Inflammaging

Current Insights into miRNA and lncRNA Dysregulation in Diabetes: Signal Transduction, Clinical Trials and Biomarker Discovery

Contact Info

Product

Resources

About

Challenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-limited Settings: Conclusions From the Council for International Organizations of Medical Sciences–Ibero-American Network of Pharmacogenetics and Pharmacogenomics Meeting

Cited by 13 publications

References 29 publications

<p>Prevalence of <em>CYP2C8*2</em> and <em>*3</em> among Eritreans and its Potential Impact on Artesunate/Amodiaquine Treatment</p>

<p>Prevalence of <em>CYP2C8*2</em> and <em>*3</em> among Eritreans and its Potential Impact on Artesunate/Amodiaquine Treatment</p>

Emerging Vistas for the Nutraceutical Withania somnifera in Inflammaging

Current Insights into miRNA and lncRNA Dysregulation in Diabetes: Signal Transduction, Clinical Trials and Biomarker Discovery

Contact Info

Product

Resources

About

<p>Prevalence of <em>CYP2C82</em> and <em>3</em> among Eritreans and its Potential Impact on Artesunate/Amodiaquine Treatment</p>

<p>Prevalence of <em>CYP2C82</em> and <em>3</em> among Eritreans and its Potential Impact on Artesunate/Amodiaquine Treatment</p>